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Assessing the feasibility of mobilisation 
of C0–C3 cervical segments to reduce 
headache in migraineurs
Abstract
Background: Migraine headache poses a major public health problem. Pharmacological treatment 
is the most common management strategy, however patients are increasingly seeking alternative 
treatments. The Watson Headache® Approach (targeted and sustained non-manipulative mobilisation 
on C0–C3) is used to reduce headache symptoms and provide sustained relief. This research aimed 
to assess this approach as a treatment strategy for migraine headache and to provide data to inform a 
subsequent randomised controlled trial. 
Methods: One-hundred-and-one migraineurs were randomised to either the ‘treat now’ (n=54) or 
‘wait list’ (n=47) group. Physiotherapists trained in the approach provided the intervention. Participants 
received six sessions. Outcome data were collected as a headache diary, including: headache score, 
headache days, headache duration, pain and medication use. Follow up was immediately post 
treatment (FU0) and at 3 (FU3), 6 (FU6) and 12 months (FU12). 
Results: Between-group analysis found no difference between the wait list group at baseline 2 and 
the treat now group at FU0 for any of the variables of interest. Within-group analysis found that after 
treatment participants experienced a reduction in headache intensity (P=0.007) and duration (P<0.001), 
had fewer headache days/28 days (P<0.001), hours of severe migraine headache (P<0.001) and used 
20% fewer medications compared with before treatment (P<0.001). 
Conclusion: The Watson Headache® Approach shows promise as a potential strategy for migraine 
management, however further work is required to assess the efficacy of this technique in a larger, 
randomised placebo-controlled trial. Future studies should aim to identify those most likely to benefit 
from treatment and who may be at risk of potential adverse event.
Key words: ■ Migraine ■ Headache ■ Watson Headache® Approach  
■ Cervical mobilisation ■ Physiotherapy
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M
igraine headache poses a major public 
health problem, both economically 
(Bloudek et al, 2012; Berra et al, 
2015) and socially (Le et al, 2011; 
Winter et al, 2012; Chu et al, 2013; 
Stewart et al, 2013). Eleven per cent of people 
worldwide suffer from migraine headaches (Stovner 
et al, 2007). Migraine prevalence is highest between 25 
and 55 years (Lipton and Bigal, 2005) and peaks at age 
40 (Hazard et al, 2009). The condition is three times 
more common in women (Schwartz  et al, 1998). Work 
function may be affected, with reduced performance 
accounting for >75% of lost productive time (Stewart 
et al, 2008). 
The 2013 International Headache Society 
classification describes primary headaches (migraine, 
tension type headache and trigeminal autonomic 
cephalalgias). It also provides comprehensive 
definitions of headache types and diagnostic criteria 
for >300 headaches. Although the categorisation of 
headache types might suggest different causative 
factors, a ‘continuum’ of headache has been 
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hypothesised linking migraine to tension type 
headaches (Featherstone, 1985; Nelson, 1994; Bronfort 
et al, 2001; Cady et al, 2002; Bartsch, 2005). It has 
been further postulated that migraine headache may 
have its origins in the cervical spine (Bartsch and 
Goadsby, 2003; Bartsch, 2005).
The neuroanatomical basis for migraine headache 
as cervicogenic may rest with the convergence of 
nociceptive afferents from the receptive fields in 
the upper three cervical nerves within the trigeminal 
nerve field (Bogduk, 2001; Bartsch and Goadsby, 
2003). Should a continuum exist between migraine, 
tension type headache and cervicogenic headache, the 
causative mechanisms could be shared. The basis for 
the physical treatment for cervicogenic (Dunninget al, 
2016) and tension type headache (Linde et al, 2016) 
has been made. If the same treatment linkage could 
be demonstrated for migraine headache, this would 
strengthen the case for accepting the continuum 
theory.
Most headache treatment is self-care (Boardman 
et al, 2003) through medication (Vickers et al, 
2004). However, many pharmaceutical treatments 
are suboptimal (Linde et al, 2005) and, in cases of 
medication overuse, can augment headache (Colás 
et al, 2004). Consequently, many patients seek non-
pharmacological solutions, such as acupuncture or 
manipulative therapy (Bronfort et al, 2001; Astin and 
Ernst, 2002; Schabert and Crow, 2009).
Systematic reviews of trials (Bronfort et al, 2001; 
Astin and Ernst, 2002) comparing spinal manipulative 
therapy (chiropractic and osteopathic) with various 
other modalities show limited evidence of the 
effectiveness in the amelioration of various headache 
types, including migraine.
Reproduction of familiar headache for migraine 
and tension type headache using sustained spinal 
mobilisation has been demonstrated by Watson and 
Drummond (2012). Using targeted and sustained 
(non-manipulative) mobilisation techniques on 
the C0–C3 segments, Watson (2011) has claimed 
reproduction and lessening of familiar headache 
or migraine symptoms (with and without aura) and 
would expect appreciable relief from symptoms 
within five treatments. These claims have, until now, 
remained untested within the context of a pragmatic 
clinical trial. 
STUDY AIMS
 ■ To observe the impact of targeted mobilisation of 
C0–C3 segments on the intensity, frequency and 
duration of headache, including migraine (with 
and without aura), in migraineurs. 
 ■ To provide within-subject data to inform the size 
of the treatment effect in order to provide an 
accurate power calculation for a future randomised 
controlled trial (RCT). 
 ■ To provide between-subject pilot data to assess the 
feasibility of a ‘wait list’ methodological approach 
that could be used in a future RCT.
 ■ To assess the acceptability of the approach for a 
migraineur population.
METHODS
Study design
A wait list RCT was conducted in which participants 
were randomised to receive treatment immediately 
(‘treat now’ group) or delayed intervention (‘wait list’ 
group). Both groups provided baseline data (BL1) 
at recruitment. The intervention (treat now) group 
then proceeded to receive treatment over a period 
of 3–6 weeks. Outcome assessment was conducted 
28 days (4 weeks) after treatment completion (FU0) 
with subsequent follow-ups at 3 (FU3), 6 (FU6) and 
12 (FU12) months. The wait list group experienced 
a time delay before treatment during which it 
acted as control. The wait list group completed a 
second round of outcome measures 4 weeks prior 
to receiving any treatment. This provided data to 
compare with the FU0 outcomes for the intervention 
group and acted as a second baseline (BL2) for the 
wait list controls in order to assess steady state. 
Within-group comparison permitted estimation 
of effect size and helped inform a sample size 
estimate for any future definitive RCT. At each 
data collection point, the data were combined for 
within-group analysis of treatment effect comparing 
BL1 with each data follow-up point. All follow-up 
data were collected by postal administration of 
self-report outcome measures. The study design is 
summarised in Figure 1 and the protocol in Figure 2.
The study was approved by the NHS NRES 
Manchester Central Ethics Committee (number 
06/Q1407/86).
Patient recruitment
Once potential participants had consented, they were 
contacted by telephone for assessment against the 
entry criteria, see Box 1. Most had received a previous 
diagnosis of migraine from either a neurologist 
or GP. After eligibility was confirmed against the 
International Headache Society diagnostic algorithm 
for the existence and nature of migraine, eligible 
participants were sent a battery of baseline measures 
to complete (BL1).
Headache-specific outcome 
measures
Twenty-eight day headache diaries were posted 
to participants for completion at home. Data were 
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Recruitment from: Migraine Action Association*; GP practices*;  
local neurology units*; local employers*; public advertisement†  
and other† (e.g. word of mouth)
Participants contact researchers
Patient information and consent forms 
sent
Consent given; forms returned
Criteria met
Data entry for BL1 completed
Allocation to physiotherapists
Assessment by designated physiotherapist
Start of filter 2: Identification of red flags
Allocation to group
Criteria not met
Wait list
Present
Medical referral
Exclusion from study
Reproduction of signs  
and symptoms
No reproduction of signs and 
symptoms
Absent
Treat now
Excluded from study
Basic data collected 
and coded
Telephone screen applying filter 1
 Baseline 1 (BL1) assessment 
sent
Completed questionnaires 
returned to researchers
Baseline 2 (BL2) assessment completed and returned; BL2 data entry completed
Five additional treatment sessions offered; completion 
between 3 and 6 weeks
*Participants were contacted via an intermediary and invited to contact the researchers 
†Participants contacted researchers directly in response to gaining knowledge about the study
Figure 1. Study design including the schedule for the assessment and intervention
*Treatment completed in no less than 3 weeks (two sessions a week) and no more than 6 weeks, in order to facilitate flexibility in scheduling for both 
the participant and the therapist. BL1= initial baseline; BL2 = second baseline for wait list; FU0 = follow up immediately post treatment; FU3 = follow-up 
3 months post treatment; FU6 = follow-up 6 months post treatment; FU12 = follow-up 12 months post treatment. Participants completed a 28-day 
headache diary, the 36-item Short Form Health Survey (SF-36) and the Hospital Anxiety and Depression Scale (HADS) for BL1 and 2, FU0, 3, 6 and 12.
Whole group Group allocation Schedule of assessment and intervention
Participants 
screened, 
consented 
and entered 
into the 
study
BL1: 
28-day 
diary, 
SF-36, 
HADS
Wait list
BL 2: 
(repeat of 
BL1)
*Treatment FU0
Start of 
extended 
follow-up period
FU3 FU6 FU12
Treat 
now *Treatment FU0
Start of extended 
follow-up period FU3 FU6 FU12M
in
im
is
at
io
n
Figure 2. Study protocol flowchart
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collected at baseline (BL1), immediately post-
treatment (FU0) and then at 3 (FU3), 6 (FU6) and 
12 months (FU12) post treatment. The wait list group 
had an additional baseline assessment (BL2) prior to 
receiving intervention, then follow-up assessments 
at 0, 3, 6 and 12 months following treatment, see 
Figure 1. The diary included the following outcome 
measures:
 ■ The headache score (headache severity) (Vickers 
et al, 2004) 
 ■ Headache days (converted into number of days 
with one or more headaches every 28 days)
 ■ Duration of headache (hours)
 ■ Number of hours of migraine headache
 ■ The frequency at which a headache-related 
medication was used. (Participants were advised 
to continue their normal medication regimen.) Dose 
was not recorded and only medications related to 
headaches were recorded (triptans, painkillers and 
anti-inflammatories).
While the study collected data on all headaches, 
a reported headache score of 4 (‘I find it difficult to 
concentrate and can do only undemanding tasks’) and 
5 (‘Intense, incapacitating headache’) were reported as 
severe migraines (Vickers et al, 2004). This has face 
validity and broadly correlates with qualitative reports 
of ‘migraine’ in the headache diaries.
In addition, a quality of life questionnaire, the 
36-item Short Form Health Survey (Brazier et al, 
1992) and the Hospital Anxiety and Depression Scale 
(Zigmond and Snaith, 1983) were completed at baseline 
and posted back to the lead researcher. The effects of 
headache on work, domestic and social activities were 
recorded together with a pain visual analogue scale. 
These data are not reported in this paper.
Allocation of participants
Consecutive sampling was used; all those who met 
the entry criteria where eligible for the study. Once 
BL1 data collection was completed, participants 
were allocated to the treat now or wait list groups 
by minimisation (Treasure and MacRae, 1998). 
The minimisation factors were age, sex, diagnosis 
(migraine with and migraine without aura), headache 
score at baseline and number of years of headache 
disorder (chronicity). Allocation was done by the chief 
investigator (ID) using the MINIM software package 
(Evans and Day, 1995), which did not allow subsequent 
changes to be made. The allocation was then passed to 
the research assistant(s) (KC and LN) for processing. 
Intervention
Allocation to physiotherapist
Three physiotherapists working in private practice 
in different geographical locations in the North of 
England participated. All had attended the 2-day 
Watson Headache® Approach course and were using 
this technique in clinical practice. Once allocated to 
receive treatment, the participant was able to choose 
which of the physiotherapy practices he or she wanted 
to attend.
At the initial session, the physiotherapist screened 
for red flag symptoms and whether participants’ 
familiar headache (with or without aura) could be 
reproduced by applying specific, skilled pressure 
to the cervical spine as described by Watson and 
Drummond (2012). The headache(s) ceased on 
removal of pressure. If these requirements were met, 
patients continued with five additional sessions, which 
had to be completed within a minimum of 3 and 
maximum of 6 weeks. 
The Watson Headache® Approach
This approach (Watson and Drummond, 2012; 2014) 
is based on the well-established Maitland approach to 
spinal mobilisation (Maitland et al, 2005). Manual, 
digital pressure is exerted on bony prominences of the 
cervical spine, using them as levers to create inter-
vertebral movement to normalise range and alignment. 
Although variation exists in grading, pressures tend 
to be slow and deliberate; there are no high velocity 
or thrusting techniques. 
A key difference between Maitland’s approach and 
Watson’s is the gradation of pressure. Maitland uses 
oscillating pressures that are graded from 1 to 4, where 
grade 1 is the lightest pressure and 4 is a low amplitude 
movement at the end of the available range. Watson 
predominantly  uses sustained (non-oscillatory) 
Maitland grade 4, pushing into joint resistance 
(stiffness). The Watson Headache® Approach is also 
multifaceted, incorporating other interventions such 
as exercise and advice. Only the cervical mobilisation 
element was assessed in this study. 
Box 1. Inclusion and exclusion criteria 
assessed at recruitment interview
Inclusion criteria
 ■ Aged ≥18 years 
 ■ Meet the criteria for diagnosis of migraine 
headache (International Headache Society 
classification 1.1) 
Exclusion Criteria
 ■ Onset of headache disorder <1 year
 ■ Onset at age ≥50
 ■ Pregnancy
 ■ Cerebral or cervical malignancy
 ■ Physiotherapy for headache or cervical 
conditions within the previous 12 months
 ■ Participation in any health-related research 
projects within the previous 12 months
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Sample size
We estimated the sample size with α=0.05 and 80% 
power using a two-sided paired t-test approach. Using 
data provided by Vickers et al (2004) and assuming no 
correlation between the baseline and 12-month scores 
(the most conservative estimate), for a baseline mean 
headache score of 24.6 (standard deviation [SD]: 14.1) 
and a 12-month mean score of 16.2 (SD: 13.7) the 
required sample size was 45. Allowing an estimated 
attrition of 30% at 12 months, the sample size for a simple 
before–after design should be inflated to 65. For a two-
group design, a total sample size of 70 (pre-attrition=100) 
would allow for an assumed weak intraclass correlation 
coefficient (ICC) of up to 0.016 (design effect=1.5). A 
total of 50 patients per group was therefore required.
Blinding
It was not possible to blind participants to group 
allocation. Therapists did not know which group 
participants were allocated to, but it is possible 
participants may have broken blinding during a therapy 
session. Due to staff resourcing, research staff collecting 
data were not blinded to participant group membership. 
However, as all outcome measures were administered 
remotely by post and by self-report diary, there was little 
opportunity for the introduction of bias.
Analysis
Between-group analysis between FU0 (treat now) and 
BL2 (wait list) used an independent groups t-test for all 
stated variables. This was the only randomised control 
element of the study. A generalised linear mixed effects 
model was used for between-group assessment of five key 
variables: mean monthly headache score; mean headache 
days every 28 days; mean duration of headache; number 
of severe migraine headaches; and medication use. This 
maximised the dataset by estimating the correlation/
covariance between terms using all available data, thus 
avoiding the need for interpolation of missing data and 
post hoc adjustment. 
Participants were fitted as a random variable and 
different covariance structures were examined (those 
minimising the Akaike information criteria were 
reported). Model diagnostics were assessed, e.g. 
normality of residuals, and appropriate transformation 
of the data was undertaken where required. Only the 
most recent baseline data were used and time was fitted 
as an ordinal variable where BL1, FU0, FU3, FU6 and 
FU12 were -1, 0, 3, 6 and 12 months, respectively. The 
group*time interaction term was included. Data were 
analysed using SPSS 21. 
 RESULTS
The study commenced in September 2007 and ended 
in July 2012. Trial information was sent to the 626 
people who expressed an interest in taking part. 
The numbers of participants recruited and retained 
at each stage of the study after enrolment are given 
in Figure 3.
Between-group analysis
Table 1 gives baseline data for the treat now group 
at BL1 and the wait list group at BL1 and BL2. 
Minimisation was successful in providing baseline 
balance for potentially important prognostic variables. 
There was some variation in all of the dependent 
variables between BL1 and BL2, with BL2 scores 
being lower than BL1 (suggesting improvement). This 
reached a statistically significant level for number of 
headache days every 28 days. No other variables were 
statistically significant.
A comparison was made between wait list and 
treat now groups’ BL2 and FU0 data, respectively, for 
primary and all secondary outcome measures (Table 2). 
Not all participants completed treatment (treat now 
n=37/54 (69%); pre-treatment wait list n=44/47 (94%)). 
Significantly less medication (-8.36) was used 
at FU0 compared to BL2 (Table 2). The remaining 
descriptive results in Table 2 were all in favour of 
the FU0 group. For example, participants in the FU0 
group experienced 10 hours fewer severe migraines 
than those in the wait list group (BL2) and also had 2 
days fewer headaches every 28 days, suggesting less 
severe and less frequent headaches over all.
Within-group analysis
A combined analysis of the wait list and treat now 
groups compared data at BL1 with data at FU0, FU3, 
FU6 and FU12. First-order autoregressive covariance 
minimised the Akaike information criteria for all mixed 
effects models, and was used throughout. Results 
were checked in a sensitivity analysis by using the 
non-parametric Kruskal–Wallis between-groups test 
at each time-point and the conclusions were consistent 
with the mixed models.
Headache intensity
Headache intensity (measured by headache score) 
did not require transformation before analysis. There 
was no significant difference due to group (p=0.8, 
as expected), see Table 3, or group*time – i.e. there 
was no difference between the groups at parallel time 
points – (P=0.5, as expected), see Figure 4. Table 3 
shows that headache scores were significantly higher 
at BL1 than at FU0 (P=0.007), FU3 (P=0.019) and 
FU6 (P=0.038) indicating a reduction in severity at all 
follow up time point up to FU6. Significance was not 
reached between BL1 and FU12 (P=0.117).
Headache days
Following a square root transformation of data, no 
significant difference was found between the groups 
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Assessed for 
eligibility (n=171)
Randomised (n=114)
Patients with baseline data (n=101). Location of recruitment:
• Migraine Action (n=23)  • General practice (n=38)  
• Local neurologist (n=0) • Local employers (n=12)  
• Public ad/other (n=28)
Allocated to wait list (control):
• Received intervention (n=47)
• Did not receive intervention 
(n=0)
Lost to follow-up post treatment at:
• 0 months: n=20*
• 3 months (20+4) n=24
• 6 months (24+2) n=26
• 12 months (26+3) n=29
*Includes 6 participants in whom 
headache could not be reproduced 
by the mobilisation (failed filter 2)
Total: n=18 participants 
47 (allocated) minus 
29 (attrition) 
Allocated to treat now:
• Received intervention (n=54)
• Did not receive intervention 
(n=0)
Lost to follow-up post treatment at: 
• 0 months  n=17*
• 3 months (17+5) n=22
• 6 months (22+5) n=27
• 12 months (27+1) n=28
*For five of the 17 participants, 
headache could not be reproduced 
by the mobilisation (failed filter 2)
Total n=26 participants
54 (allocated) minus 
28 (attrition)
Excluded (n=57): 
• Did not meet inclusion 
criteria (n=51) 
• Declined to participate 
(n=6)
No data provided at 
baseline (n=13)
Enrolment
Allocation
Follow-up
Analysis
Figure 3. Recruitment and retention of participants during the study
in the number of headache days overall (P=0.8, as 
expected), or at any time point (P=0.9, as expected), 
see Figure 5. There was, however, a significant 
improvement over time (P<0.001) for both groups after 
treatment compared to BL1, and this reduction persisted 
for all time points up to and including FU12 (Table 3). 
The mean reduction in the number of headache days 
every 28 days between BL1 and FU0–FU12 was 3 days, 
which translates into an additional 36 headache-free 
days a year for each participant.
Headache duration
Following log transformation (with 1 unit perturbation) 
of data, there was no significant difference in headache 
duration (hours) due to group (P=0.6, as expected), 
or group*time (P=0.7, as expected), see Figure 6. A 
significant reduction was found in headache duration 
over time from baseline (p<0.001) see Table 4. BL1 
participants experienced fewer hours of headache 
after treatment, and this reduction persisted up to and 
including FU12. 
The estimate of the magnitude of reduction was 
calculated as exp(4.3)–exp(3.6)=37 hours. This 
indicates that post treatment, participants experienced 
37 fewer hours of headache compared with BL1. The 
reduction persisted for at least 1 year, suggesting 
that 144 hours fewer headache were experienced 
after treatment. 
Severe migraine headache
Following square root transformation before analysis, 
no significant difference in number of hours of severe 
migraine headaches (defined as 4 and 5 on the headache 
score) was found with group (P=0.9, as expected), or 
group*time (P=0.7, as expected), see Figure 7, but 
there was a significant change over time (P<0.001), see 
Table 4. The estimate of the magnitude of reduction 
was calculated as exp(2.4)–exp(1.6)=6 hours. After 
treatment, participants experienced 6 fewer hours 
of headache compared with BL1, and this reduction 
persisted for at least 1 year. Extrapolated over the 
year (given that significance was maintained for 12 
months), participants experienced 72 fewer hours of 
severe migraine headache post-treatment.
Medication use
Following square root transformation before 
analysis, no significant difference was found in 
mean medication use between the groups (p=0.5, 
as expected), see Figure 8, or group*time (p=0.3, 
as expected), see Table 4. There was a significant 
reduction in medication use over time (p<0.001), 
with the estimated magnitude of reduction being 
exp(2.6)–exp(2)= 6 medications. This indicates that 
after treatment participants used six fewer medication 
doses compared with BL1 and that this reduction 
persisted for at least 1 year. This represents a reduction 
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Table 1. Summary of baseline data for participants (n=101)
Variable All 
participants† 
(n=101)
Treat now (BL1)
(n=54)
Waiting list (BL1)     
(n=47)
Waiting list (BL2)   
(n=47)
Median age, years* (interquartile range) 46.0 
(37.5–54.0)
46.0 
(36.8–54.0)
47.0 
(38.0–56.0)
47.0 
(38.0–56.0)
Female gender*  
(%)
80 
(79.2)
44 
(85.0)
36 
(77.0)
36 
(77.0)
Headache days/28 days (mean) 
(standard deviation)
12.76 
(6.65)
12.00 
(6.43)
13.19 
(6.94)
11.25 
(7.40)§,#
Migraines per month, hours (mean)      
(standard deviation)
22.97 
(38.16)
23.46 
(6.43)
22.40 
(40.30)
21.50 
(40.25)∫
Pain¶ (mean) 
(standard deviation)
48.0 
(17.8)
46.0 
(17.8)
50.0 
(17.8)
50.1 
(21.5)§
Medication use per month      
(interquartile range)
12.0 
(7.0–28.0)
11.0 
(6.8–21.0)
16.0 
(7.0–32.0)
13.5 
(5.3–28.0)§
Migraine without aura*  
(%)
59 
(58.0)
31 
(58.0)
28 
(60.0)
28 
(60.0)
Time since diagnosis, years* (mean)     
(standard deviation)
22.8 
(13.4)
23.4 
(14.0)
22.1 
(12.7)
22.1 
(12.7)
Headache score*  
(standard deviation)
2.63 
(0.64)
2.64 
(0.63)
2.62 
(0.66)
2.60 
(0.78)§
*Minimisation factors; †this column represents combined data for both groups (TN and WL) at BL1; #p=0.027 (95% CI: 0.21–3.29) between BL1 and 
BL2 for related samples t-test; §n=44; ∫n=43
Table 2. Between-group differences comparing the treat now group at FU0 and the wait list group at BL2
Variable Group Mean            
(standard deviation)
Mean differences 
FU0 – BL2
P-value 95% confidence 
interval
Hours of severe 
migraine (4 and 5 on the 
headache score)
Treat now (n=37) 11.5 (20)
-10.03 0.17 -24.55 to 4.49
Wait list (n=43) 21.5 (40.3)
Mean headache score
Treat now (n=37) 2.3 (0.9)
-0.32 0.91 -0.7 to 0.05
Wait list (n=44) 2.6 (0.8)
Headache days/28 days
Treat now (n=37) 8.9 (6.9)
-2.33 0.15 -5.51 to 0.85
Wait list (n=44) 11.3 (7.4)
Headache duration          
(hours/month)
Treat now (n=37) 67.1 (74.2)
-12.88 0.45 -46.36 to 20.60
Wait list (n=44) 80.7 (76.4)
Medication use            
(number/month)
Treat now (n=37) 10.3 (9.9)
-8.36 0.009* -14.56 to -2.51
Wait list (n=44) 19.9 (18.1)
in mean medication use of approximately 20%. 
Extrapolated over the year, the data suggest that a 
total of 72 fewer headache-related medications were 
used per participant post treatment. Table 4 also 
reveals an additional and unexpected reduction in 
mean medication usage between FU3 and FU6 (mean 
reduction of 2.191 at FU3 versus 1.950 at FU6), which 
represents a reduction of 27% in mean medication 
usage between BL1 and FU6.
Sample size for future trial
We used our results to estimate the required sample 
size for a future trial based on a primary outcome of 
mean headache score. To allow for the two-group 
randomised trial design, the ICC was calculated using 
the difference between mean BL1 and FU12 headache 
scores and estimating variance components. The mean 
differences for the treat now and wait list groups were 
0.14 and 0.06, respectively, giving var(group)=0.06 
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Table 3. Time effect: differences from BL1 in headache duration, severe 
migraine headaches and medication use
Variable Time 
point
Mean 
difference
P-value 95% confidence 
interval
Headache 
score
FU0 -0.252 0.007 -0.07 to -0.44
FU3 -0.255 0.019 -0.04 to -0.47
FU6 -0.235 0.038 -0.01 to -0.46
FU12 -0.178 0.117 0.05 to -0.40
Headache 
days/28 
days
FU0 -3.111 0.001 -1.82 to -4.40
FU3 -2.906 0.001 -1.54 to -4.27
FU6 -3.803 0.001 -2.55 to -5.06
FU12 -3.833 0.001 -2.38 to -5.28
Data output taken from a generalized linear mixed model
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Figure 4. Mean headache scores for the treat 
now (n=21) and wait list (n=17) groups
Wait list Treat now
Table 4. Within-group comparisons of headache duration, migraines and 
medication use (n=38)
Variable Mean
95% confidence 
interval
Headache duration 
(hours)
Baseline 4.275 4.06 to 4.50
FU0 3.668 3.38 to 3.95
FU3 3.764 3.40 to 4.03
FU6 3.575 3.28 to 3.87
FU12 3.715 3.42 to 4.01
Severe       
migraine 
headaches (hours)
Baseline 2.373 2.03 to 2.72
FU0 1.643 1.26 to 2.03
FU3 1.643 1.21 to 2.09
FU6 1.821 1.42 to 2.22
FU12 1.727 1.33 to 2.12
Medication use 
(number every 
28 days)
Baseline 2.618 2.43 to 2.80
FU0 2.093 1.87 to 2.32
FU3 2.191 1.97 to 2.41
FU6 1.950 1.73 to 2.17
FU12 2.155 1.88 to 2.43
Data output taken from a generalized linear mixed model
(mean headache score: 2.47) and 63 who did not 
(mean headache score: 2.72). There was no statistically 
significant difference (p=0.058) between the BL1 
scores of those who dropped out and those who did not. 
There was even less difference between the scores at 
FU0 (drop-out mean: 2.37; non-drop-out mean: 2.30; 
p=0.7). As such, attrition did not appear to skew the 
results of the study but did reduce its ability to detect 
between-group differences.
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Figure 5. Headache days per 28 days for the 
treat now (n=21) and wait list (n=17) groups
and var(error)=0.65. Taking a mean group size of 22 
at FU12, an ICC of 0.15 was obtained, which should 
be taken into account in sample size calculations if a 
randomised trial design is used in future.
Attrition effects
Attrition in this study was high. A sensitivity analysis 
of mean headache score data revealed that 38 patients 
provided complete scores up to and including FU12 
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Figure 6. Headache duration for treat now 
(n=21) and wait list (n=17) groups
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Figure 7. Severe migraine headache in the 
treat now (n=21) and wait list (n=17) groups
Wait list Treat now
Adverse events
Three participants reported adverse events and were 
removed from the study. Two adverse events were 
related to an increase in headache frequency and 
severity. Both participants were men in their early 
50s whose migraines had been diagnosed many years 
before the start of the study. A third person (a female 
in her early 60s) reported unilateral anaesthesia and 
paraesthesis in her upper and lower limbs 24 hours 
post treatment, which resolved within hours. This 
was not reported to the research team for 7 days. 
Subsequent medical investigation at the time of report 
found no neurological dysfunction and she has had 
no re-occurrence of the symptoms since the episode.
DISCUSSION
Reflecting upon the adverse events, the neurological 
symptoms experienced by one participant is a 
particular cause for concern, given the link between 
migraine and stroke (Malik et al, 2015). Although no 
cause–effect relationship is presumed, the temporal 
proximity of the symptoms and treatment is sufficient 
to advise future caution. Future studies should overtly 
advise participants that should they experience these 
symptoms – whether or not in the context of treatment 
– they should treat it as a medical emergency and 
seek immediate attention. Despite these unexpected 
negative aspects of the study, the overwhelming 
effect of the Watson Headache® Approach on the 
cohort was positive.
Between-group data did not show any statistically 
significant differences between the variables tested, 
except for medication use each month, see Table 
2. This statistical difference is equivocal, however, 
as the wait list group at initial baseline (BL1) had 
a much higher medication use per month than the 
treat now group (16; interquartile range: 7–32 versus 
11; interquartile range: 6.8–21, respectively), see 
Table 1. This suggests that the wait list group was 
more medication-dependent at BL1 and therefore 
more likely to be so post-treatment. As such, no 
credible statistically significant difference between 
groups was seen. However, within-group analysis of 
the combined data showed a consistent reduction in 
medication use, which was significant over 12 months. 
On average, 72 fewer medications for each person a 
year were used over the 12 months after treatment. 
Despite baseline imbalance for medication 
use, all other potentially important variables were 
balanced well. Descriptive analysis showed that for 
all the parameters of interest, there was a substantial 
beneficial change in favour of the treat now group at 
FU0 compared with the wait list group at BL2. The 
lack of statistical difference between the groups may 
be due to a type II error. This potential issue could be 
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Figure 8. Mean medication use in the treat 
now (n=21) and wait list (n=17) groups
Wait list Treat now
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remedied with the recruitment of larger numbers of 
participants. Given that an ICC of 0.15 was observed, 
a much larger study may be required to detect a 
difference in the primary outcome measure (mean 
headache score) for this type of staggered design. 
However, a simpler parallel group design would 
possibly have much smaller sample size requirements 
and therefore be preferable. 
Overall, within-group analysis showed a much 
more positive outcome. Statistically significant 
changes compared to baseline were seen for all 
follow-up time points up to 1 year except for the 
headache score, which was only significant up to 6 
months. Despite the statistical significance for these 
variables, the question of clinical significance needs 
to be addressed. This is a difficult assessment as the 
significance of any lasting change is a matter of some 
subjectivity. However, in their study on acupuncture 
and headache, Vickers et al (2004) estimated that 
a 35% change in headache score was clinically 
significant. In their study, acupuncture reduced the 
number of headache days by a projected 22 days 
a year. In the present study, the mean difference 
in headache score was only 0.25 points. Headache 
duration, number of migraine hours and medication 
use were all reduced at follow-up but the extent to 
which these are clinically significant is debatable and 
requires further analysis. It is unclear whether changes 
observed can be attributed to the intervention without 
a control group in the post-treatment part of the study.
It is possible that the clinical effects of treatment 
could be latent. In this regard, the significant reduction 
in medication use is of interest due to the problems 
associated with overuse of painkilling medication 
(Andrasik et al, 2010; Fontanillas et al, 2010; 
Kristoffersen and Lundqvist, 2014a; 2014b; Lai et 
al, 2014). The favoured approach to the treatment of 
medication overuse is currently withdrawal; however 
there is no clear consensus on how this should be 
achieved (Kristoffersen and Lundqvist, 2014a). 
Table 4 shows a surprising reduction in medication 
usage between FU3 and FU6 and beyond the initial 
reduction seen between BL1 and FU0. If this were 
to be associated with a reduction in the frequency, 
duration or severity of headache/migraine, then it 
would be logical to expect that data collected after 
FU6 would show an improvement.
Although headache days, duration and severity 
show no change after FU0, hours of headache for the 
most severe migraines were unexpectedly reduced 
between FU6 and FU12. It is possible that these data 
have unexpectedly captured a relationship linking a 
reduction in medication use with a reduction in the 
total hours of the most severe headaches. This is 
speculative and further analysis of these data will 
explore whether or not this phenomenon exists. Should 
this association exist, then it is possible that the 
Watson Headache® Approach could serve as a ‘bridge’ 
to assist migraineurs with medication withdrawal. 
It is possible that the observed events are a natural 
variation in the data, which might also explain the 
statistical significant difference seen between BL1 
and BL2 for the wait list group for headache days 
every 28 days. A more plausible explanation for 
this, however, could be the anticipatory effect of 
future treatment.
The data broadly suggest that the Watson 
Headache® Approach for the treatment of migraine 
and other headaches shows promise. Given that the 
technique incorporates other interventions, such 
as exercise and advice, and that participants only 
had six sessions, the results of the present study 
could be a conservative estimate of its true effect. 
Although there is no conclusive evidence for physical 
interventions to the neck for the amelioration of 
migraine headache, there are some encouraging signs 
that physical treatment directed towards the neck may 
be effective. These include such modalities as spinal 
manipulation (Bronfort et al, 2001; Astin and Ernst, 
2002; Schabert and Crow, 2009), acupuncture (Vickers 
et al, 2004; Linde et al, 2005; Wang and Young, 2011), 
massage (Lawler and Cameron, 2006; Chatchawan et 
al, 2014) and a combination of massage and spinal 
manipulation (Noudeh et al, 2012). 
The mechanism by which physical treatment 
works is unclear; however, Vargas (2008) suggests 
that central sensitisation of the nervous system 
is a protagonist in the development of migraine. 
This sensitisation could be precipitated by hyper-
excitability of pain-transmitting second-order 
neurones in the trigemino-cervical nucleus (TCN) 
caused by afferent input from dysfunctional cervical 
segments (Watson and Drummond, 2014) resulting 
in sensitisation of the trigeminal field through the 
nucleus caudalis (which has connections in the upper 
cervical spine). If sensitised, this can increase sensory 
traffic to the thalamus and cortex (Cady, 2007). As 
the trigeminal nerve supplies the meninges and its 
vascular structures, it is conceivable that sensitisation 
manifests itself as a pulsating headache. 
Should neural sensitisation of the trigeminal nerve 
field and its associated connections be the culprit, 
one explanation as to why physical neck treatment 
is effective is that desensitisation occurs when a 
disrupting intervention to the cervical region reduces 
excessive neuronal signalling from the neck. This 
‘Mobilisation of the upper three cervical vertebrae 
appears to have an ameliorative effect on migraine 
and associated headaches.’
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may occur in manipulation, massage, acupuncture or 
mobilisation – all of which may have an inhibitory 
effect on the neuronal activity being transferred 
through the TCN, which acts as a conduit between 
the trigeminal nerve and the thalamus. This, however, 
is speculative.
Watson and Drummond (2012; 2014) have shown 
that mobilisation of the upper three cervical vertebrae 
appears to have an ameliorative effect on migraine 
(and associated headaches). However, this present 
study is the first to show this within the context of 
a pragmatic trial. The Watson Headache®Approach 
may be effective as it reproduces migraine (and 
other) headaches (including aura). Once produced, 
the manual pressure over the cervical vertebra 
is sustained.
 The former allows for anatomical specificity 
of treatment and the latter, accommodation of 
the nociceptive afferent signals, thus leading to 
desensitisation and, it would appear, long-lasting 
effect. This combination of pressure and reproduction 
can be sustained for up to 90 seconds, during which 
the familiar headache should be produced and then 
lessened (Watson and Drummond, 2014). This 
lessening of pain/symptoms may be a marker for 
desensitisation of the trigeminal nerve field. The 
combination of these two key factors appears to be a 
unique element of the Watson Headache® Approach. 
The linkage of tension type headache (a primary 
headache) and migraine headache has been put 
forward in the convergence or continuum theory 
(Schade, 1997; Cady et al, 2002; Cady, 2007; Vargas, 
2008; Turner et al, 2015). Yet physical treatment for 
tension type headache may also include procedures 
that focus on the cervical area (Hammill et al, 1996; 
Chatchawan et al, 2014; France et al, 2014). Given 
the link between treatment for migraine and tension 
type headache, the prospect of the two having their 
genesis in the cervical spine is compelling for those 
who centre their treatment in this anatomical area.
The finding of this study adds to the body of 
evidence suggesting that treatment applied to the 
neck may ameliorate migraine and that the lessening 
of migraine following treatment has a lasting effect. 
It is possible, but by no means proven, that the 
sensitisation that is believed to be at the centre of 
migraine headache could be produced by unspecified 
pathology in the upper cervical spine. However, 
causality has yet to be demonstrated.
For many, self-medication remains the main 
treatment of choice, possibly due to its relatively 
low cost and convenience. Further endorsement 
of pharmaceutical solutions include botulinum 
toxin therapy for the relief of chronic migraine 
(Aurora et al, 2010; Diener et al, 2010), which is 
recommended under specific circumstances by the 
National Institute for Care and Clinical Excellence 
(2012). It is interesting to note that the placement of 
the injection needles for the delivery of botulinum 
toxin  (and saline placebo) is similar to the locations 
used by manual therapists and acupuncturists. It 
is also interesting to note that the studies showed 
considerable reduction in migraine days for the 
control group as well as the intervention group 
(Aurora et al, 2010; Diener et al, 2010). It is possible 
that the success of the placebo control group was 
caused by a mechanical effect due to the insertion 
of the needle, a chemical effect of the saline, or 
both, resulting in the desensitisation of the TCN. 
Given the relatively high cost of botulinum toxin 
(Torgovnick, 2011), it is a wonder that saline is not 
used as a cheaper and safer first-line treatment.
Limitations
Despite the results, this present study has limitations. 
The most severe limitation was the attrition rate, 
which may have led to bias. If more patients who 
had perceived benefit from the treatment remained 
in the study, the data might be skewed in favour 
of the intervention, resulting in an overestimate of 
the treatment effect. This might suggest that the 
populations (those who continued in the study and 
those who dropped out) may be different. However, 
sensitivity analysis of mean headache score provides 
non-significant evidence that those who dropped out 
started with the highest headache scores, suggesting 
no significant difference between these subgroups 
at baseline. This alleviates some concerns that the 
characteristics of those who dropped out differed 
significantly to participants retained on the study.
A cogent reason for attrition following a single 
treatment may have been replication of the migraine 
symptoms during treatment, despite participants 
being warned of this in the patient information sheet. 
This reaction is understandable, as it runs counter 
to most treatment interventions that seek to avoid 
the reproduction of symptoms. It is more difficult to 
explain why 25 participants who received treatment 
did not provide any post-treatment data. It is possible 
that people saw this as an opportunity to receive 
treatment not normally routinely provided in the 
public sector and were not otherwise committed to 
the study. To mediate against this potential problem, 
future studies might consider it prudent to offer an 
ethically-sound inducement to participants to ensure 
complete data collection post-treatment. 
‘The finding of this study adds to the body of evidence 
suggesting that treatment applied to the neck may 
ameliorate migraine and that the lessening of migraine 
following treatment has a lasting effect.’
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The wait list control was also a potential problem, 
in that it only allowed a single point in time when 
between-group analysis could be assessed. Future 
studies should be comparative in nature in order that 
follow-up comparisons can be made throughout the 
entire follow-up period. 
A further problem of this present study was very 
slow recruitment. De Hertaogh et al (2009) have 
identified the difficulties in recruitment associated 
with this kind of study. Despite recruiting from 
many sources, uptake was extremely slow. After 5 
years of recruitment, despite considerable interest 
in the study only 101 patients gave consent and 
provided baseline data. The reason for this remains 
unknown, but perhaps the study seemed too arduous 
or the inducement of headache during assessment 
and treatment deterred participants. Further work 
should explore this.
CONCLUSIONS
Although limited by a small sample size, this study 
has provided some evidence to support the use of the 
Watson Headache® Approach for the treatment of 
headaches, including migraine. This further supports 
the theory that migraine headaches have their genesis 
in the upper cervical spine. Although the within-group 
evidence consistently points to a continued effect, 
more work is required – particularly in the form of a 
fully-powered placebo controlled comparative RCT 
conducted nationally or internationally. 
Mobilisation seemed to produce an effect worthy 
of further investigation. In a future trial, the sample 
size could be larger than expected if the headache 
score is retained as the primary outcome measure. The 
use of a wait list group has some value but is unable 
to give between-group analysis throughout follow-up 
in the way that a fully powered comparative study 
could. Finally, the acceptability of this treatment 
is not universal, as evidenced by the low uptake 
and high attrition rate. However, it is clear that this 
treatment could be effective for some. 
For those who are able and willing to engage 
with this approach, the outcome appears broadly 
positive. Future studies should investigate who is 
most likely to benefit and who may be at greater risk 
of potential side-effects. The theory that the Watson 
Headache® Approach could be used as a ‘bridge’ to 
reduce medication use, and so minimise medication 
overuse, may warrant further investigation. IJTR
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